<DOC>
	<DOCNO>NCT00983346</DOCNO>
	<brief_summary>OBJECTIVES - Primary : To evaluate bone anabolic effect bortezomib patient smolder myeloma . - Secondary : To evaluate effect bortezomib natural history smolder myeloma .</brief_summary>
	<brief_title>Effect Low Dose Bortezomib Bone Formation Smoldering Myeloma Patients</brief_title>
	<detailed_description>Smoldering multiple myeloma ( SMM ) usually follow expectantly without therapy . The overall risk progression active multiple myeloma estimate 20 % first year diagnosis ( Kyle et al , 2007 ) . An angiogenic switch postulate pivotal event progression MGUS smolder myeloma . Two trial advance refractory MM patient test hypothesis use Thalidomide antiangiogenic agent association biphosphonates show effect disease progression ( Barlogie et al , 2008 ) . The ubiquitin-proteasome pathway , show essential cellular degradative system myeloma cell , also regulate bone formation though effect osteoblast differentiation ( Pennisi et al. , 2008 ) . Retrospective analysis ALP variation 2 large Bortezomib trial refractory set confirm find . In SUMMIT trial ( Zangari , et al. , 2005 ) , 77 patient evaluate . The medium increment ALP level respond patient ( patient &gt; 50 % decrease paraprotein ) upon completion 3 cycle therapy statistically high individual less partial response ( week 8 , P=0.0015 ; responder range , 62-837 mL/L ) . In APEX trial ( Zangari et al . 2005 ) , 422 patient analyze ; 217 patient randomized bortezomib , 205 dexamethasone . Within bortezomib arm , increment serum ALP level responder patient ( &gt; CR ) statistically high week 3 ( P=0.014 ) , week 6 ( P=0.002 ; responder rage , 31-272 mL/L ) week 9 ( P=0.036 ) . Comparing responder patient arm study , observe significantly high median ALP increase bortezomib compare dexamethasone arm ( P &lt; 0.01 ; responder run , 31-272 mL/L ) ( Zangari et al. , 2007 ) . A 25 % increase ALP ( N=105 ) week 6 also strong indicator associate quality response ( P &lt; 0.0001 ) also time progression ( 206 vs. 169 day ) relative patient less 25 % increase ALP ( N=228 ; P=0.01 ) ( Zangari et al. , 2007 ) . We test bone anabolic effect bortezomib cohort smolder multiple myeloma patient . Study rationale selection drug dos VELCADE show produce anabolic bone effect ( increase bone ALP osteocalcin ) relapsed/refractory patient . This study examine bone anabolic effect patient smolder myeloma , median age 67 year , frequent evidence osteopenia associate lytic bone disease . Risk disease progression estimate 10 % per year patient population . The primary aim trial determine effect short course ( i.e . 9 cycle ) low-dose Bortezomib bone remodel disease progression . The dose bortezomib use trial 0.7 mg/m2 low dose show efficacy 3 large monotherapy trial bortezomib . Seventeen percent patient APEX 9 % patient CREST 24 % SUMMIT trial treat 0.7 mg/m2 dosage . Bortezomib give day 1 , 8 , 15 , 22 42 day reduce incidence possible drug relate side effect .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients diagnosis smolder multiple myeloma Male Female patient age ≥ 18 year old Ability provide write informed consent ( obtain prior participation study relate procedure perform ) understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study Male subject agree use acceptable method contraception duration study . Serum M protein ≥3 g/dL and/or Bone marrow plasma cell ≥10 % Absence anemia , renal failure , hypercalcemia , lytic bone lesion ANC ≥ 1.5 x 109 /L Hemoglobin ≥ 10g/dl Platelets ≥ 100 x 109 /L AST ALT ≤2.5 x ULN Serum bilirubin ≤2.0 x ULN Platelet count &lt; 100 109/L within 14 day enrollment . Absolute neutrophil count &lt; 1.0 109/L within 14 day enrollment . Creatinine clearance &lt; 30 mL/minute within 14 day enrollment . Patient Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum human chorionic gonadotropin ( hCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy . Patients currently take bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>myeloma</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>smolder myeloma</keyword>
</DOC>